These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24733351)

  • 21. [Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].
    Kuhlmann-Gottke J; Duchow K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1299-305. PubMed ID: 26369765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Present systems and future needs for risk assessments of biologicals: the perspective of the regulator in the People's Republic of China.
    Xia Y; Zhang Z; Li M
    Rev Sci Tech; 1995 Dec; 14(4):1185-91. PubMed ID: 8639955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2010 World Stem Cell Summit--part 1. October 4-6, 2010, Detroit, MI, USA.
    Vertès A
    IDrugs; 2010 Dec; 13(12):819-21. PubMed ID: 21154132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
    Lucas-Samuel S; Ferry N; Trouvin JH
    Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International regulatory considerations pertaining to the development of stem cell-based veterinary medicinal products.
    Jeon BS; Yi H; Ku HO
    J Vet Sci; 2021 Jan; 22(1):e6. PubMed ID: 33522158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lost in translation? Accountability and governance of clinical stem cell research in China.
    Zhang JY
    Regen Med; 2017 Sep; 12(6):647-656. PubMed ID: 28976821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reflection on the governance of clinical stem cell research and applications in China.
    Chen H
    Regen Med; 2017 Sep; 12(6):593-597. PubMed ID: 28976281
    [No Abstract]   [Full Text] [Related]  

  • 29. Global regulatory developments for clinical stem cell research: diversification and challenges to collaborations.
    Rosemann A; Bortz G; Vasen F; Sleeboom-Faulkner M
    Regen Med; 2016 Oct; 11(7):647-57. PubMed ID: 27622527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory considerations for pluripotent stem cell therapies.
    Carpenter MK
    Prog Brain Res; 2017; 230():151-163. PubMed ID: 28552227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Broad support for regulating the clinical implementation of future reproductive techniques.
    Hendriks S; Vliegenthart R; Repping S; Dancet EAF
    Hum Reprod; 2018 Jan; 33(1):39-46. PubMed ID: 29190346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products.
    Cavagnaro J; Silva Lima B
    Eur J Pharmacol; 2015 Jul; 759():51-62. PubMed ID: 25814257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strengthening Health Products Regulatory Systems to Enhance Access to Quality Health Products in the Asia-Pacific.
    Lim JCW
    Ther Innov Regul Sci; 2018 Nov; 52(6):751-754. PubMed ID: 29714589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Special considerations concerning regulatory requirements and drug development for peptides and biotech products in the EU.
    Braun A; Gassmann R; Kraus K; Lorenzi G; Weigel U
    Pharm Acta Helv; 1996 Dec; 71(6):447-58. PubMed ID: 8997177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stem-Cell Therapy Advances in China.
    Hu L; Zhao B; Wang S
    Hum Gene Ther; 2018 Feb; 29(2):188-196. PubMed ID: 29284300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A critical assessment of the scientific basis, and implementation, of regulations for the safety assessment and marketing of innovative tobacco-related products.
    Combes RD; Balls M
    Altern Lab Anim; 2015 Sep; 43(4):251-90. PubMed ID: 26375889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herbal Products Regulations in a Few Countries-A Brief Overview.
    Bhat BB; Udupa N; Sreedhar D
    Curr Drug Discov Technol; 2019; 16(4):368-371. PubMed ID: 30394210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Regulatory science research to facilitate the development of cell/tissue-processed products].
    Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.